Biotechnology and its Applications — Class 12 Biology Notes & Practice

Take a breath. If you have opened this page because Chapter 10 looks like a wall of names — cryIAc, humulin, ADA, GEAC, RiceTec — and you are quietly panicking, you are in exactly the right place, and you are not behind. This chapter has almost no calculation in it. It is a chapter of stories: a bacterium that keeps a folded weapon in its pocket, a company that built a human hormone out of two half-genes, a four-year-old girl whose immune system had a missing recipe page, and a courtroom fight over the word “basmati”. Once the stories click, the names stop being scary and start being labels you can hang things on.

Here is the honest position. Chapter 10 is the applications half of biotechnology. Its partner chapter, Chapter 9, gives you the toolkit — restriction enzymes, vectors, plasmids, PCR, bioreactors, downstream processing. This chapter takes that toolkit outdoors and asks: so what did we actually build with it? If you have not met the toolkit yet, or it has gone hazy, spend twenty minutes with the tools and steps of recombinant DNA technology first. Everything below will land twice as hard afterwards. But if you have no time for that today, do not worry — I will re-explain every tool at the moment you need it, from absolute zero.

What does the board actually want? Chapter 10 sits inside Unit IX, Biotechnology and its Applications, which carries 12 marks in the Class 12 Biology scheme. The syllabus line for this chapter is short and you should read it like a checklist: application of biotechnology in health and agriculture — human insulin and vaccine production, stem cell technology, gene therapy; genetically modified organisms and Bt crops; transgenic animals; biosafety issues, biopiracy and patents. That is the whole territory. Nothing outside it can be asked, and everything inside it is fair game. Notice that stem cell technology has been given its own named place in the current syllabus — it used to be a footnote, and it is not one any more.

So this page is built to be the only thing you need for this chapter. Plain explanation first, always from zero. Then worked exam questions with the mark split written out, because in a theory chapter the real skill is not knowing the answer, it is packing the answer so the examiner can find the marks. Then sticky-note callouts for the things students most often get wrong. Then a ten-question practice worksheet with full model answers hidden behind Show Answer buttons, so you can test yourself honestly. If you came searching for biotechnology and its applications class 12 important questions, or you typed something like Bt cotton cry gene explained into a search bar at eleven at night, or you needed gene therapy ADA deficiency class 12 notes that actually explain why the treatment has to be repeated — all of that is below, in order.

One promise before we start. I am not going to ask you to memorise anything until you understand it. Memorising cryIAc is miserable. Understanding that a protoxin is a folded pocket knife that only opens in one particular pocket — and that the pocket is an alkaline caterpillar gut, which is why the same protein is completely harmless in your acidic stomach — that is a thing you will still remember in March. We will build every fact on top of a picture like that.

What You’ll Learn

Your Game Plan

1. Day 1 — agriculture. Read the crop sections: why we modify crops, Bt cotton and the cry genes, how the toxin works, RNA interference, biofortification. Draw the four-step Bt flow from memory on a blank page before you sleep.
2. Day 2 — health. Read insulin, gene therapy, stem cells, vaccines, molecular diagnosis. These five are the highest-yield health topics in the chapter. Say the insulin story out loud to someone, even a wall.
3. Day 3 — animals and ethics. Transgenic animals (learn the five reasons as a numbered list, not a paragraph), biosafety, GEAC, biopiracy, patents, the three famous cases.
4. Day 4 — the worked examples only. Come back and read just the Example cards on this page. Cover the answer, write yours, then compare the mark split. This is the single highest-value hour you will spend on this chapter.
5. Day 5 — the worksheet. Ten questions, closed book, timed. Then open the answers and mark yourself harshly. Anything you lost a mark on goes onto a single revision card.
6. The night before the exam — the callouts. Read only the Key Idea, Exam Tip and Common Mistake boxes on this page. They take about twelve minutes and they are the difference between 9 and 12.

Study Notes

Where Biotechnology Meets Real Life

Start with the plainest possible definition, because the board loves it and because it stops you from thinking biotechnology means only gene splicing. Biotechnology is the use of living organisms, or of things made by living organisms, or of parts of them, to make products and services that people want. That definition is deliberately wide. It covers a woman in a village setting curd overnight. It covers a brewery. It covers a hospital lab growing a fungus for penicillin. And yes, it also covers a scientist stitching a human gene into a bacterial plasmid.

People sometimes split this into two eras. The old era — traditional biotechnology — used whole organisms doing what they already do naturally. Fermentation, curd, bread, vinegar, antibiotics from moulds. That world is covered in detail in the chapter on microbes in human welfare, and if you have read it you already have half of the vocabulary you need here. The new era — modern biotechnology — began when we learned to open up DNA, take out a chosen piece, and put it somewhere it was never going to go on its own. That single ability is what turned biotechnology from cookery into engineering.

Why does that matter for this chapter? Because every single application below is one sentence long once you see the pattern. Find a useful gene. Move it into an organism that is easy to grow or is the one that needs it. Let that organism make the product. That is Bt cotton, that is humulin, that is the hepatitis B vaccine, that is Rosie the cow. Fifteen sections, one idea, repeated with different cargo.

Two words you will meet constantly, so let us kill the confusion now. A genetically modified organism, or GMO, is any organism whose genetic material has been deliberately altered by us using laboratory techniques. A transgenic organism is the common special case: one that is carrying a gene brought in from a different species. Bt cotton is transgenic, because the cry gene came from a bacterium. A plant in which we have switched off one of its own genes is genetically modified but is not, strictly speaking, carrying a transgene. In board answers, “GM” is the safe umbrella word and “transgenic” is the precise word for a foreign gene.

Before we move on, hold on to one perspective point, because it makes the ethics sections at the end of the chapter far easier to write about. Every technology in this chapter was invented to solve a real, painful problem: children dying of an enzyme they could not make, diabetics reacting badly to pig insulin, farmers spraying poison on their own fields week after week. The criticisms are real too. But an answer that only lists dangers, with no sense of what problem was being solved, reads thin. An answer that holds both reads mature, and mature answers get the top band.

↑ Back to top

The Three Critical Research Areas

If someone stopped you in a corridor and asked what biotechnology research actually consists of, you could answer in three moves. This is a small, quiet part of the syllabus that turns up as a one-mark or two-mark question far more often than students expect, and it is free marks if you have the three areas ready.

• Providing the best catalyst. Every biotechnological process needs a worker: an enzyme, or a whole organism that behaves like a factory. Research area one is finding or improving that catalyst — an enzyme that works faster, at a friendlier temperature, or a microbe that produces more of what we want.
• Creating optimal conditions for the catalyst to work. A brilliant enzyme in the wrong conditions produces nothing. So we engineer the environment: correct pH, correct temperature, correct oxygen supply, correct nutrients, correct stirring. In industry this means designing the vessel — the bioreactor — around the organism.
• Downstream processing. The product is now sitting in a soup of cells, unused nutrients and waste. Getting it out, purifying it, formulating it and keeping it stable is its own science, and it is often the most expensive part of the whole process.

Think of it as cooking. Area one is choosing the cook. Area two is giving the cook a proper kitchen. Area three is plating the dish and getting it to the table without it going cold. Amateurs obsess over the cook. Industry knows that the plating — downstream processing — is where the money goes.

There is one more framing sentence worth carrying into every answer in this chapter. Biotechnology has given three big things to human welfare: therapeutics that were previously impossible or unaffordable, diagnostics that catch disease before symptoms appear, and genetically engineered crops that need less spraying and waste less harvest. Health, detection, agriculture. If a question ever says “write a note on the applications of biotechnology” and you go blank, write those three headings and the paragraphs will come.

↑ Back to top

Why We Genetically Modify Crops

Humans have been modifying crops for roughly ten thousand years. Every farmer who kept seed from the best plant and threw away the rest was running a slow, blind genetics experiment. That is conventional breeding, and it worked spectacularly — wild teosinte became maize, wild grasses became wheat. But conventional breeding has two hard limits, and understanding those two limits is the honest answer to “why bother with genetic engineering at all?”

Limit one: you can only shuffle what is already in the gene pool. If no wheat plant anywhere carries a gene for resistance to a particular fungus, no amount of crossing wheat with wheat will conjure one. You are dealing a new hand from the same deck. Limit two: it is slow and imprecise. Every cross drags thousands of unwanted genes along with the one you wanted, and you spend generations backcrossing them out.

Genetic engineering lifts both limits at once. It lets you bring in a gene from a completely different kingdom — a bacterial gene into a cotton plant — and it lets you bring in that gene alone, without the baggage. If the genetics of crossing and selection is still shaky for you, revise the ideas of gene, allele and dominance from the chapter on principles of inheritance and variation.

So what have GM plants actually been used for? The syllabus gives a clean list, and you should be able to reproduce it. Learn it as six items:

• Tolerance to abiotic stresses. Crops that survive cold, drought, salt or heat. These are the non-living enemies — the weather and the soil.
• Reduced dependence on chemical pesticides. A plant that defends itself is a plant nobody has to spray. This is where Bt crops live.
• Reduced post-harvest losses. A very large share of what is grown never reaches a mouth — it rots, softens or spoils between the field and the plate. Crops engineered to soften more slowly buy time.
• More efficient mineral use by plants. Plants that take up soil minerals better exhaust the soil less quickly, which slows the loss of soil fertility.
• Enhanced nutritional value. Deliberately raising the level of a nutrient that people in a region are short of. Vitamin A enriched rice is the standard example.
• Herbicide tolerance. A crop that survives a specific weedkiller lets a farmer clear weeds without hand-weeding an entire field.

Notice how these split into two families. Some make the plant tougher — against insects, weeds, weather, herbicide. Others make the harvest better — more nutritious, longer lasting, less wasteful of soil. If you can only remember one thing under pressure, remember “tougher plant, better harvest” and reconstruct the six from there.

↑ Back to top

Bt Cotton and the Cry Genes

Here is the origin story, and it starts in the soil. There is a bacterium called Bacillus thuringiensis. Its name gets shortened to Bt, and that shortening is the whole reason the phrase “Bt cotton” exists. Like many soil bacteria, when conditions turn bad it forms a spore. And while it is doing that, it also manufactures crystals of a particular protein and packs them beside the spore. Those crystals are the point of this entire section.

The crystal protein is an insecticide. Certain insects that swallow it die. Farmers and gardeners noticed this long before anybody understood the genetics, and Bt was sold for decades as a sprayable biological pesticide — you simply sprayed the bacteria, or preparations of the crystals, onto the leaves. That worked, but it had all the problems of any spray. Rain washed it off. Sunlight degraded it. It only reached surfaces you had sprayed, so a caterpillar boring inside a cotton boll never met it. And you had to keep buying it and keep applying it.

So somebody asked the obvious, brilliant question. If the killing is done by a protein, and a protein is made by a gene, why not put the gene into the plant and let the plant make its own supply, continuously, in every tissue, including the tissues a spray can never reach? That is Bt cotton. That is the entire idea. Everything else is detail.

Now the part students find fiddly: there is not one cry gene, there are many, and different ones kill different insects. This specificity is a feature, not a nuisance — it means a Bt crop can be aimed at the pest that is actually destroying it, while insects that are not on the target list walk away unharmed. Learn this small table properly; it is one of the most commonly asked pieces of factual recall in the whole chapter.

Two more points that lift a good answer into a very good one. First, notice how the gene names are written: the gene cryIAc in lower case italics, the protein Cry IAc with a capital. Gene lower case, protein capitalised — that convention runs through molecular biology and it signals to an examiner that you know the difference between a stretch of DNA and the thing it makes.

Second, and this is the elegant part, the toxin genes are transferred into the plant using standard recombinant DNA technique — the gene is isolated, inserted into a vector, and the vector carries it into plant cells, which are then regenerated into whole plants. The mechanics of cutting, ligating and delivering are exactly the ones described in the tools and steps of recombinant DNA technology. Chapter 10 assumes you know them and then simply says “the gene was transferred”.

↑ Back to top

How the Bt Toxin Actually Kills the Pest

This is the single most beautiful mechanism in the chapter, and if you understand it properly you will never again wonder why Bt cotton does not poison the people who wear the cotton. So let us go slowly, because the safety of the whole technology hangs on one detail: the toxin is not a toxin when it is made.

Think of a pocket knife folded shut. Folded, it is a lump of metal in your pocket — harmless, inert, you can sit on it. It becomes dangerous only when something opens it. The Cry protein is exactly that. The bacterium makes it, and the transgenic plant makes it, as an inactive protoxin — a big, folded, crystallised protein that cannot hurt anything, which is precisely why the bacterium that manufactures it does not kill itself, and why the cotton plant that manufactures it grows perfectly normally.

So what opens the knife? A very specific pocket. Follow the four steps.

• The insect eats it. A bollworm larva chews the cotton tissue and swallows the crystals of inactive protoxin along with its meal.
• The gut is alkaline. The midgut of these insect larvae is strongly alkaline — a high pH environment. That alkalinity dissolves the crystal, releasing the protoxin into solution. This is the step that makes everything specific.
• The protoxin is converted into the active toxin. Gut proteases trim the dissolved protoxin down, and what is left is the small, active Bt toxin. The knife is now open.
• The gut lining is destroyed. The active toxin binds to specific receptors on the surface of the midgut epithelial cells. It inserts into the membrane and creates pores. Water rushes in through those pores, the cells swell, and they lyse — burst. With its gut lining destroyed, the larva stops feeding and dies.

Now put your own stomach next to that. Human stomach contents are strongly acidic, not alkaline. The crystal does not solubilise properly, the protoxin is not converted, the knife stays folded, and the protein is simply digested like any other protein in your food. That is the safety argument in one sentence, and it is also why Bt is specific to particular insect groups — you need the right gut chemistry and the right receptors on the gut cells. An insect that lacks the matching receptor is not affected even if its gut is alkaline.

One last honest note, because good students ask it and it shows real understanding. If a Bt crop kills every susceptible bollworm in a field, the only bollworms that survive and breed are the rare ones that happen to be resistant. Over many generations, resistance can spread through the pest population — the crop stops working. This is natural selection happening in fast forward on a farm, and it is exactly the process described in the chapter on evolution. It is one of the strongest arguments for using Bt as part of a wider pest management strategy rather than as the only weapon.

↑ Back to top

Pest-Resistant Plants Using RNA Interference

Bt is one way to make a plant defend itself: give it a gene for a poison. There is a second, quieter and cleverer way, and the syllabus wants you to know it. Instead of poisoning the pest, you silence one of the pest’s own essential genes. The technique is called RNA interference, usually shortened to RNAi.

To follow this you need one fact about how genes work. A gene is a stretch of DNA. To use it, a cell copies it into a single-stranded messenger RNA, and that mRNA is then read by ribosomes to build a protein. If the mRNA is destroyed before it gets read, the protein is never made — the gene has effectively been switched off, even though the DNA is untouched. If transcription and translation feel foggy, they are built up carefully in the chapter on the molecular basis of inheritance, and this section will make far more sense afterwards.

RNA interference is a defence mechanism that already exists in eukaryotic cells. It is normally used against viruses and against jumping genetic elements. The trigger is double-stranded RNA. A cell does not usually make double-stranded RNA, so its presence is treated as an alarm signal: something foreign is here. The cell responds by chopping the double-stranded RNA into small fragments, and those fragments then act as guides — they find any single-stranded RNA in the cell whose sequence matches, and direct its destruction. The result is that a specific mRNA is silenced.

Now the application. Tobacco plants are attacked by a nematode — a tiny parasitic roundworm — called Meloidogyne incognita. It invades the roots and sets up shop, and the infestation badly reduces the yield. The strategy was this. Using an Agrobacterium vector, scientists introduced into the tobacco plant DNA designed to produce both the sense and the antisense RNA of one of the nematode’s genes. Because both strands are made in the same cell, they are complementary and they pair up — and the plant now contains double-stranded RNA matching a nematode transcript.

When the nematode feeds on the transgenic tobacco, it takes that double-stranded RNA into itself. Inside the parasite, RNA interference kicks in and the corresponding nematode mRNA is silenced. Without that protein the parasite cannot survive in the host, and the transgenic plant is protected. The parasite is not poisoned; it is disarmed using its own machinery.

↑ Back to top

Biofortification and Better Nutrition

Hunger is not only about quantity. A person can eat enough rice every day to fill their stomach and still go blind from lack of vitamin A, or become anaemic from lack of iron, or fail to grow properly from lack of protein. This is called hidden hunger, and it is enormous. Biofortification is the deliberate breeding or engineering of crops so that the staple food a population already eats carries more of the nutrient they are short of.

The word to be careful with is biofortification versus fortification. Ordinary fortification means adding a nutrient to a food after it has been produced — iodised salt, vitamin-D milk. Biofortification means the plant itself makes more of the nutrient while it is growing in the field. The advantage is enormous in practice: no supply chain, no extra cost per packet, no need to persuade anybody to buy a different product. The farmer plants the same crop and the nutrient arrives free.

The objectives of biofortification, as the syllabus frames them, are to improve the content of protein, of oils, of vitamins, of micronutrients such as iron and zinc, and to raise the quality of protein — meaning the balance of essential amino acids, not merely the total amount. Note that last one, because it is subtle and it is examinable: more protein is not automatically better protein. A protein missing an essential amino acid is nutritionally incomplete no matter how much of it you eat.

The most famous single example is rice engineered to accumulate provitamin A in the grain. Ordinary rice grains contain essentially none, which is why populations dependent on rice as the staple can suffer vitamin A deficiency even with full stomachs. Engineering the biosynthetic pathway into the endosperm gives grains that carry provitamin A — and the visible orange tint of those grains is where the popular name “golden rice” comes from. Other well-known Indian efforts include maize hybrids with roughly doubled levels of the amino acids lysine and tryptophan compared with earlier hybrids, wheat varieties with higher protein content, and carrots, spinach and pumpkin bred for higher vitamin A. Where a source gives you a precise percentage improvement, quote it; where it does not, say “substantially higher” and move on — an invented number is worse than no number.

↑ Back to top

Making Human Insulin: The Problem and the Solution

We now cross from the field to the clinic. Insulin is the chapter’s flagship story, and it is asked more often than anything else here, so we will do it properly — the problem first, then the structure, then the solution.

The problem. Insulin is the hormone that lets your cells take glucose out of the blood. People with insulin-dependent diabetes do not make enough of it and must receive it from outside. For decades, the only way to get insulin was to extract it from the pancreases of slaughtered cattle and pigs. That worked, and it saved millions of lives, but it had three real difficulties. Supply was limited by the number of animals slaughtered — you cannot scale a hormone supply by wishing. The insulin was not human insulin; it was pig or cow insulin, similar but not identical, and in some patients the immune system reacted against this foreign protein, causing allergy. And extracting a hormone from animal glands is expensive and fiddly.

The structure. Human insulin is a small protein made of two short polypeptide chains, called the A chain and the B chain, held together by disulphide bonds. But — and this is the pivot of the whole story — the body does not make the two chains separately. In the pancreas, insulin is first synthesised as a single continuous chain called proinsulin, in which the A chain and B chain are joined by an extra stretch of polypeptide called the C-peptide. That C-peptide is a kind of temporary scaffold: it holds the molecule in the right shape while the disulphide bonds form. Once its job is done, the C-peptide is enzymatically snipped out, and what is released into the blood is the mature insulin: A chain plus B chain, no C-peptide.

Why that made the engineering hard. If you simply put the human insulin gene into a bacterium, the bacterium would make proinsulin. Bacteria do not have the machinery to remove the C-peptide the way a human pancreatic cell does. So you would end up with a molecule that is not usable insulin. This was the genuine technical obstacle, and the way round it is the reason this story is in your syllabus at all.

The solution. In 1983, the American company Eli Lilly took a different route. Rather than making proinsulin and trying to process it, they prepared two separate DNA sequences — one corresponding to the A chain and one corresponding to the B chain of human insulin. Each sequence was introduced into plasmids and then into Escherichia coli, so that two separate bacterial cultures were running: one churning out A chains, one churning out B chains. The chains were then extracted from their respective cultures and combined in vitro by creating disulphide bonds between them. The result is human insulin, marketed under the name humulin. The C-peptide is never made and never needed — you simply build the two halves and clip them together yourself.

↑ Back to top

Gene Therapy and ADA Deficiency

Here is the idea in its purest form. Suppose a person has been born with a faulty copy of a gene, and because of that fault their body cannot make one particular protein. Every treatment we have ever had works around the problem — you inject the missing protein, or you replace the cells that should have made it. Gene therapy asks a different question: why not just give the cell the missing recipe page?

Formally, gene therapy is a collection of methods that allow the correction of a gene defect diagnosed in a child or an embryo, by delivering a normal, functional gene into the person’s cells or tissues so that it can take over the function of the non-functional gene. That is the definition; learn its shape, because the two halves — correcting a diagnosed defect, and delivering a functional gene to take over the function — are usually worth half a mark each.

The first clinical attempt at gene therapy was made in 1990, on a four-year-old girl with adenosine deaminase deficiency — ADA deficiency. Let us understand exactly what is wrong with her before we discuss the fix, because the mechanism of the disease explains the design of the treatment.

Adenosine deaminase is an enzyme. Its job is part of normal nucleotide housekeeping: it processes adenosine, and if it is absent the substrate builds up to levels that are toxic. The cells most sensitive to that build-up happen to be lymphocytes — the white blood cells that run your immune system. So a child who cannot make adenosine deaminase loses her lymphocytes and therefore loses her immune defence. The condition is caused by the deletion of the gene for adenosine deaminase, and it produces a severe immunodeficiency: ordinary infections become life-threatening. If the role of lymphocytes in immunity is not solid in your head, revise it from the chapter on human health and disease.

What could be done before gene therapy? Two things, and both are only partial. A bone marrow transplant can supply cells that carry a working gene — but it requires a suitable donor and is not curative for every patient. Enzyme replacement therapy, in which functional adenosine deaminase is injected into the patient, keeps the child alive — but it is not completely curative either, because the enzyme has to be given repeatedly and the patient’s own cells still cannot make it. The word your syllabus uses is that these approaches are not completely curative. Use that phrasing; it is precise and it is safe.

The gene therapy approach. Lymphocytes were taken from the patient’s blood and grown in culture outside the body. A functional ADA cDNA — a DNA copy made from the messenger RNA of the normal gene — was introduced into those lymphocytes using a retroviral vector. The corrected lymphocytes were then returned to the patient’s body, where they could now make the enzyme.

And here is the catch that every good answer includes. The cells that were corrected are lymphocytes, and lymphocytes are not immortal — they have a limited lifespan. As those corrected cells die off, the benefit fades. So the procedure has to be repeated: periodic infusions of genetically engineered lymphocytes, again and again. It is control, not cure. A permanent cure would require introducing the functional gene into cells at an early embryonic stage, so that every cell descended from them — including the ones that will go on making lymphocytes for a lifetime — carries the working copy.

↑ Back to top

Stem Cell Technology: An Elementary Idea

Your syllabus asks for an elementary idea of stem cell technology, and that phrase is a kindness — it means you are not expected to know clinical protocols. You are expected to know what a stem cell is, why it is special, what the main types are, and what we hope to do with them. Let us build exactly that, and nothing more, because in a chapter this crowded, knowing where to stop is a skill.

Almost every cell in your body is finished. A neuron is a neuron; it will never wake up one morning and become a liver cell, and when it dies it is generally not replaced by a neighbouring neuron dividing. Most specialised cells are at the end of their road. A stem cell is a cell that is not at the end of its road. It has two properties that ordinary cells lack: it can divide to produce more cells like itself — this is called self-renewal — and it can, under the right signals, differentiate into one or more specialised cell types.

Think of a company where nearly every employee has one fixed job title. Stem cells are the trainees. They can be sent to any of several departments, and when one leaves, the training programme produces another. That is really the whole concept: unspecialised, self-renewing, capable of becoming something specific.

Stem cells are usually sorted by how many things they can become — their potency. Learn these four words in descending order and you will be able to place any example you are given.

• Totipotent. Can give rise to a complete organism, including the supporting tissues around the embryo. The fertilised egg and the cells of the very first few divisions are totipotent.
• Pluripotent. Can give rise to cells of all three germ layers — that is, essentially any cell type of the body — but not to a whole organism on their own. Embryonic stem cells are the classic example.
• Multipotent. Can give rise to several related cell types within one family. Blood-forming stem cells in bone marrow can produce red cells, white cells and platelets, but not neurons.
• Unipotent. Can produce only one cell type, but retain the ability to self-renew. Some cells that maintain a single tissue behave this way.

There is also a practical split by source, and this is the split that the ethics arguments hang on. Embryonic stem cells are obtained from very early embryos and are pluripotent, which makes them extraordinarily useful and also extraordinarily contested, because obtaining them has historically involved destroying the embryo. Adult or tissue-specific stem cells are found in mature tissues — bone marrow is the best known reservoir — and are generally multipotent, so they are less versatile but ethically far less troubled. There is also a third and important route: reprogramming ordinary adult cells in the laboratory so that they behave like pluripotent stem cells, which sidesteps the embryo question entirely.

What is the hope? Regenerative medicine. If a tissue has been destroyed — heart muscle after a heart attack, insulin-producing cells in diabetes, nerve cells after a spinal injury, blood-forming cells wiped out by cancer treatment — then in principle stem cells could be directed to become the missing cell type and replace what was lost. The most established real-world use is the bone marrow transplant, which is in essence a transfer of blood-forming stem cells, and which has been in clinical use for decades. Beyond that, most applications are at various stages of research, and an honest answer says so rather than promising cures.

↑ Back to top

Vaccines Made by Recombinant DNA Technology

To see why recombinant vaccines were such a breakthrough, remember what a vaccine has to achieve. It has to show your immune system the shape of a pathogen so that memory cells are formed, without giving you the disease. Traditional vaccines did this by using the pathogen itself, either killed or weakened. That works, but it carries two burdens: you must grow large quantities of a dangerous organism, and there is always a residual worry that a weakened strain could revert or that a killed preparation was not completely inactivated.

Recombinant DNA technology offers a much cleaner route. Your immune system does not actually need the whole pathogen. It needs to see the distinctive surface protein — the antigen — that identifies that pathogen. So: identify the gene for that surface antigen, insert it into a harmless host cell such as yeast or bacteria, let the host manufacture large quantities of that single protein, purify it, and use the purified protein as the vaccine. No pathogen is ever grown. There is nothing in the vial that could cause the disease, because there is nothing in the vial but one protein.

The standard example is the vaccine against hepatitis B. The gene for the hepatitis B surface antigen is expressed in yeast — Saccharomyces cerevisiae, the same species used in baking and brewing — and the antigen produced is purified and formulated as the vaccine. The result is a vaccine that is safe by construction and can be manufactured in industrial quantities at reasonable cost. Vaccines produced in this way are often called subunit vaccines, because they contain a part of the pathogen rather than the whole thing. The immunology behind why an antigen alone is enough — antigen presentation, memory cells, primary and secondary responses — is developed properly in the chapter on human health and disease.

↑ Back to top

Molecular Diagnosis: PCR and ELISA

Treatment is useless if it arrives too late. That single sentence is the reason this section exists. Conventional diagnosis — a serum test, a urine test, a doctor examining symptoms — usually only works once the disease has advanced far enough to produce noticeable effects, by which time the pathogen has multiplied enormously. The great gift of molecular biology to medicine is the ability to detect a pathogen when its concentration is still very low, long before the patient feels ill.

There are two workhorse techniques you must know, and they detect completely different things. Get that difference right and this section is easy.

PCR — the polymerase chain reaction — detects the pathogen’s nucleic acid. Every organism carries its own DNA or RNA sequence, which is as distinctive as a signature. PCR takes a sample, uses primers designed to match a sequence unique to that pathogen, and repeatedly copies that region. Each cycle roughly doubles the number of copies, so a handful of starting molecules becomes an easily detectable quantity within a couple of hours. The consequence is what matters: a few molecules of viral nucleic acid, far too few to cause symptoms yet, can be amplified until they are visible. PCR is therefore used routinely to detect infections such as HIV in suspected cases, to detect certain gene mutations in suspected cancer patients, and to identify inherited genetic disorders. If you want the cycle-by-cycle mechanics — denaturation, annealing, extension, and the role of a heat-stable polymerase — they are set out step by step in the tools and steps of recombinant DNA technology.

ELISA — enzyme-linked immunosorbent assay — detects proteins. It works on the principle of antigen and antibody binding to each other with high specificity. There are two ways to use that. You can look for the pathogen’s own antigen — a protein belonging to the pathogen, whose presence means the pathogen itself is in the sample. Or you can look for the antibodies that the patient’s immune system has produced against that pathogen, whose presence means the patient has been exposed. The detection is made visible by linking an enzyme to the antibody used in the test; when the enzyme is given its substrate it produces a colour change, and the colour is the answer.

Which one is better? Neither — they answer different questions, and a good examiner will test whether you know that. PCR asks “is the pathogen’s genetic material here right now?” ELISA asks “is the pathogen’s protein here, or has this person’s immune system met it?” A patient could be very early in an infection, with nucleic acid present but antibodies not yet produced, in which case PCR finds it and an antibody-based ELISA does not. Equally, a patient could have cleared an infection but still carry antibodies, in which case ELISA reports past exposure while PCR finds nothing.

One further diagnostic technique belongs here and is worth two clean sentences in an answer. A single-stranded piece of DNA or RNA, tagged with a radioactive or fluorescent label, will bind to its complementary sequence and to nothing else. That tagged molecule is called a probe. If you allow a probe to meet the DNA of a patient’s cells, it will bind wherever the complementary sequence exists, and the label will show you where. With a radioactive probe, the hybridised sequence is detected by autoradiography. If the mutated sequence is present, the matching probe binds and reports it; a probe designed for the normal allele will not hybridise at that altered site under stringent conditions. This is how a mutation can be identified directly. The same principle of complementary base pairing underlies DNA fingerprinting, which is explained in the chapter on the molecular basis of inheritance.

↑ Back to top

Transgenic Animals and Why We Make Them

A transgenic animal is an animal whose genome has been altered by the introduction of a foreign gene. Mice, rats, rabbits, pigs, sheep, cows and fish have all been made transgenic. The overwhelming majority are mice, simply because mice breed fast, are small, are cheap to maintain and are mammals like us.

The question the board asks is almost always “why are transgenic animals produced?” and the answer is a list of five reasons. Students who learn it as a flowing paragraph lose marks, because the marker is counting distinct reasons. Learn it as five numbered items and write it as five numbered items.

Take a moment on Rosie, because she is the example everyone is asked for. In 1997, Rosie became the first transgenic cow. She produced milk that was enriched with a human protein — human alpha-lactalbumin — at a level of about 2.4 grams per litre of milk. The point of the exercise was nutritional: milk carrying a human protein is more suitable for human babies than ordinary cow milk, which is balanced for a calf rather than for an infant. Note the specific human protein by name, because “Rosie made human milk” is not a scoring answer; “Rosie produced human-protein-enriched milk containing human alpha-lactalbumin” is.

↑ Back to top

Biosafety, Ethics and the GEAC

Everything we have discussed so far is a capability. This section is about the question that follows every capability: should we, and under whose supervision? Students often skip these pages because they contain no mechanism to memorise. That is a mistake — the ethics material is short, it is easy, and it appears in the paper.

Start with the concern itself. Genetic modification of organisms can have unpredictable results when those organisms are introduced into an ecosystem. Nature is a web, not a list, and pulling one thread moves others. So most countries have created regulatory bodies to look at the proposals in advance rather than to clean up afterwards. In India, that body is the Genetic Engineering Approval Committee, abbreviated GEAC. It is the name your syllabus uses; in current official usage the same committee is generally referred to as the Genetic Engineering Appraisal Committee, and if you write either expansion with the abbreviation GEAC you will be understood. Its function is twofold and you should give both halves: it makes decisions about the validity of research involving genetically modified organisms, and it decides on the safety of introducing genetically modified organisms for public services.

What are the actual worries? They fall into three families, and organising your answer into these three families is far more impressive than a scattered list.

• Ecological concerns. A gene introduced into a crop might move into wild relatives. An insect-resistant crop might affect insects that were never the target, including harmless or useful ones. Pests may evolve resistance, so that the benefit fades and the ecological disturbance remains. And introducing a modified organism into an ecosystem can have consequences nobody predicted.
• Health and food-safety concerns. Any new protein in the food supply raises the question of whether some people will react to it, so novel foods need testing rather than assumption. This is a reason for careful evaluation, not a reason for panic, and a good answer says so.
• Social, economic and ethical concerns. Who owns the seed? Who owns the knowledge? Does a farmer become dependent on buying seed each season? Is it acceptable to patent a living organism at all? These are questions about power and fairness rather than about biology, and they lead directly into the next section.

There is also a broader ethical strand worth one sentence: many people feel that the genetic modification of organisms without regard for their intrinsic value raises a moral question independent of any measurable harm. You do not have to agree with it. You do have to be able to state it fairly, because “discuss the ethical issues” means discuss, not dismiss.

↑ Back to top

Biopiracy, Patents and the Basmati Story

We finish where the biology meets the law, and it is the most human part of the chapter. Start with the two definitions, because everything else hangs on them.

A patent is a right granted by a government to an inventor, giving them exclusive control over the use of their invention for a fixed period, in exchange for describing the invention publicly. Think of it as a receipt for an idea: you show the world what you made, and in return you are the only one allowed to sell it for a while. The bargain is meant to encourage invention, because inventing is expensive and copying is cheap.

Biopiracy is the term used for the use of bio-resources by multinational companies and other organisations without proper authorisation from the countries and people concerned, and without compensatory payment. Notice the two elements — no authorisation, and no compensation. Both have to be present. Buying a plant legally and paying for it is trade; taking the knowledge and the material and paying nobody is biopiracy.

Why does this arise so sharply between countries? Because biological wealth and industrial capacity are unevenly distributed. The industrialised nations are financially rich but generally poor in biodiversity and in traditional knowledge about it. The developing nations are rich in both. Traditional knowledge — how to use a plant, when to harvest it, what it treats — is often thousands of years old, held communally, written nowhere, and owned by no single named person. Patent law, by contrast, is designed around a single named inventor with a novel idea. That mismatch is the crack through which biopiracy happens: knowledge that belonged to everyone, for centuries, can be claimed as new by someone who has just written it down in the right format.

Three cases are named in your syllabus, and you should be able to give the crop, the claim and the outcome for each.

The 1997 basmati patent is the one to know in most detail, because it is named explicitly in the syllabus. NCERT notes that 27 documented varieties of basmati are grown in India. The United States Patent and Trademark Office granted the RiceTec patent on basmati lines produced by crossing Indian basmati with semi-dwarf varieties. Two things made it notorious. First, the patent covered rice lines related to varieties already grown for generations on the subcontinent, which meant the claimed novelty drew heavily on existing material and knowledge. Second, the rights claimed touched the use of the name basmati itself, a name that identifies a place and a farming tradition, not a company’s product. India challenged the patent, several claims were withdrawn, and the surviving scope was narrowed.

What changed because of these fights? Two things worth a sentence each in a long answer. Countries became far more careful about documenting their traditional knowledge, so that prior art can be produced quickly the next time a claim is filed — you cannot patent what is already written down and public. And international discussion moved towards frameworks in which communities that hold traditional knowledge are recognised and compensated when it is used commercially. The Indian Parliament has also revised national legislation on patents so that the interests of Indian farmers and the biological wealth of the country are given proper protection.

↑ Back to top

Biotechnology and its Applications Class 12 Important Questions — Practice Worksheet

Ten questions, written fresh for this page. Cover the answers, write yours on paper — actual paper, actual pen, in full sentences — and only then open the accordion. Reading an answer feels like learning and is not. Writing one and finding out where it fell short is where the marks come from. Give yourself about forty minutes for the whole set.

↑ Back to top

One Small Step, Every Single Day

You do not have to finish this chapter tonight. You do not have to feel confident about all fifteen sections by the weekend. What you have to do is smaller and far more powerful: pick one thing today — the four-step Bt flow, or the six words of the insulin sentence, or the five reasons transgenic animals are made — and know it so well that you could explain it to somebody who has never heard of a gene. Tomorrow, pick the next one. Fifteen small, honest days beat one heroic all-nighter every time, because what you build slowly stays built. That steady, patient, one-improvement-a-day habit has a name in Japanese, kaizen, and it is the only study method that has never let a student down. Come back to this page tomorrow. It will be here, and so will you, one section stronger.

↑ Back to top